Trial Profile
A Randomized Phase 2/3 Study of Apatinib as Third Line Treatment in Patients With Metastatic Gastric Carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Aug 2013
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Gastric cancer
- Focus Therapeutic Use
- 05 Aug 2013 Results published in the Journal of Clinical Oncology.
- 11 Jul 2011 Actual end date (Dec 2010) added as reported by ClinicalTrials.gov.
- 11 Jul 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.